Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRACE phase 3 relacorilant randomized-withdrawal study in endogenous Cushing syndrome
NL-OMON54706Phase 3Completed
- Sponsor
- Corcept Therapeutics
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of relacorilant in endogenous Cushing's syndrome (3 arms), sponsored by Corcept Therapeutics. Primary endpoints: Loss of blood pressure response during randomized-withdrawal phase, Treatment discontinuation during randomized-withdrawal phase and 1 more. Started Jun 2020; status: completed.
02
Drugs
relacorilant
03
Conditions
endogenous Cushing's syndrome
Beyond the preview
Go deeper on NL-OMON54706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54706.